Low-Grade Serous Ovarian Cancer — Trials

Low-Grade Serous Ovarian Cancer — Trials · CancerIndex

Clinical trials

Registered studies

6 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 5
Recruiting: 3
Ph III recruiting: 1
Growth YoY: —
Industry share: 60%
Top sponsor: Verastem, Inc.
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03564340	Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers	recruiting	Phase 1 / Phase 2	890	Regeneron PharmaceuticalsINDUSTRY	10	Sep 25, 2026	clinicaltrials
NCT06072781	A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer(RAMP 301)	recruiting	Phase 3	270	Verastem, Inc.INDUSTRY	16	Aug 14, 2026